---

Drug Therapy Analysis - Epistaxis Patient (28/M)

Drug Identification (Brand → Generic)

---

1. DRUG-DRUG INTERACTIONS (DDIs)

🔴 MAJOR / HIGH SEVERITY

• Ondansetron is a well-documented QT-prolonging agent. The FDA issued a safety advisory specifically for this risk. Alprazolam can also have cardiac effects at higher doses.
• Risk: Torsades de Pointes (TdP) and fatal arrhythmia, especially if patient has undetected electrolyte abnormalities.
• Action required: Baseline ECG before starting ondansetron; monitor QTc interval. Avoid in patients with baseline QT prolongation, hypokalemia, or hypomagnesemia. - Rosen's Emergency Medicine, Adults section

• NSAIDs, including aceclofenac, blunt the antihypertensive effect of ARBs (telmisartan) by inhibiting prostaglandin-mediated renal vasodilation.
• NSAIDs + ARBs together = "triple whammy" risk if any diuretic is co-administered - acute kidney injury (AKI) is well described.
• NSAIDs can cause sodium/water retention, worsening hypertension and potentially precipitating further epistaxis.
• Action required: Avoid NSAID use in this hypertensive patient if possible; use paracetamol alone for pain. Monitor renal function and BP.

• NSAIDs reduce the antihypertensive efficacy of beta-blockers by inhibiting prostaglandin-dependent vasodilation.
• Both Telma and Met XL are being given for BP control - the NSAID in Acupara undermines both simultaneously.
• Action required: Same as above - avoid NSAID component if pain relief is needed SOS.

• Xylometazoline is a sympathomimetic alpha-1 agonist. Systemic absorption (even from nasal route) can raise BP.
• This directly opposes the antihypertensive effect of telmisartan and metoprolol.
• In a patient already admitted for epistaxis (likely from hypertension), using a vasoconstrictor nasal spray causes local nasal mucosal vasoconstriction for hemostasis but systemic alpha-agonism can raise BP - a paradox.
• Action required: Use with caution; limit duration to <5 days; monitor BP during use. This spray is somewhat appropriate locally for epistaxis control, but systemic effects are a concern in a hypertensive patient.

---

🟡 MODERATE SEVERITY

• PPIs raise gastric pH. Cefpodoxime proxetil requires acidic pH for optimal absorption - its bioavailability is reduced by ~30-40% when given with PPIs.
• Action required: Separate administration by 2 hours; give cefpodoxime before PPI. Monitor clinical response to antibiotic.

• Both are CYP2C8/CYP2C9 substrates. Pantoprazole inhibits CYP2C8 to a minor extent, which can marginally raise montelukast plasma levels.
• Clinically not usually significant, but worth noting in polypharmacy.

• Additive CNS depression (sedation, respiratory depression). Ondansetron mildly inhibits CYP3A4, which is the primary metabolic enzyme for alprazolam - this can increase alprazolam plasma levels.
• Action required: Use minimal effective doses; monitor sedation level.

---

2. DRUG ERRORS

• Giving a combination NSAID-analgesic SOS to a patient on Telma + Met XL for hypertension is a prescribing error in a hypertensive epistaxis context.
• The NSAID component worsens hypertension - the very factor likely causing or exacerbating the epistaxis.
• Better option: Prescribe paracetamol alone for pain if analgesia is needed. Avoid aceclofenac component entirely.

• GTN/Nitroglycerin is used for angina/acute coronary syndrome. For a 28/M with epistaxis as the primary complaint with no documented cardiac indication, its presence raises questions.
• If the intent is to manage hypertension-related epistaxis, GTN can lower BP rapidly but is usually reserved for hypertensive emergency with end-organ damage.
• Query: Is there a documented indication for GTN in this patient? If the patient develops acute hypertension (hypertensive crisis), short-acting antihypertensives (IV labetalol, oral amlodipine) are preferable to GTN unless there is concurrent myocardial ischemia.

• Ondansetron injection TID for a young patient admitted primarily for epistaxis - is there an active indication for IV antiemetic? Vomiting as a complaint must be clearly documented. Over-use of IV ondansetron increases QT risk unnecessarily.

---

3. DRUG-RELATED PROBLEMS (DRPs)

---

4. DRUG DUPLICATION

• Not exactly a duplication, but having two antihypertensives without documented uncontrolled hypertension on monotherapy should be queried. These work by different mechanisms so combination is acceptable IF indicated, but epistaxis raises concern that BP is poorly controlled regardless.

---

5. CLINICAL CONCERN - EPISTAXIS & THE DRUG LIST

---

SUMMARY TABLE

---

1. Stop or replace Acupara - the NSAID component worsens hypertension and impairs hemostasis in an epistaxis patient.
2. Perform ECG before continuing IV ondansetron TID - QTc monitoring is mandatory.
3. Limit Nasomist to acute use only (≤3-5 days); counsel on rebound congestion risk.
4. Review indications for Cepodem (antibiotic), Restyl (benzodiazepine), and Nitrocin (GTN) - justify clearly in case notes.
5. Monitor BP closely - dual antihypertensives + NSAID is a problematic combination; consider if BP is optimally controlled.
6. Check coagulation profile (PT, platelet count) given NSAID use and ongoing nasal bleeding.